Thierry Thaure
CEO/Co-founder
GT Metabolic Solutions
GT Metabolic Solutions develops magnetic compression anastomosis technology for minimally invasive bariatric and metabolic procedures. Its MagDI™ System creates side-to-side duodeno-ileal anastomoses without incisions, sutures, or staples, promoting natural tissue healing while supporting durable weight loss and glycemic control in obese patients with or without type 2 diabetes. The first-generation Magnet received FDA De Novo marketing authorization in July 2024.
- Medical Devices
- Healthcare Technology
- Hardware
- Biotechnology
Updated 6 days ago
Funding
Raised to date
$4.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
JPNot disclosed · Series C
Announced Oct 2026 · from article date
Disclosed cumulative: $4.8M
2/2
RoundDateAmountValuationInvestors
Founders
Michel Gagner
CMO/Co-founder
Product
Problem
Traditional bariatric and metabolic surgeries often require incisions, sutures, or staples to create anastomoses, which can lead to complications and impede natural tissue healing. These invasive techniques may result in longer recovery times and increased patient discomfort.
Solution
GT Metabolic Solutions has developed a magnetic compression anastomosis technology designed for minimally invasive bariatric and metabolic surgeries. This technique eliminates the need for incisions, sutures, or staples by using magnets to achieve anastomosis, promoting natural tissue healing. The MagDI™ System facilitates side-to-side duodeno-ileal anastomosis, creating a partial diversion of intestinal contents intended to facilitate durable weight loss and improve glycemic control in obese patients with or without type 2 diabetes. This less-invasive approach aims to improve patient outcomes and reduce the risks associated with traditional surgical methods.
Target Audience
The primary target audience includes bariatric and metabolic surgeons seeking minimally invasive surgical solutions, as well as obese patients with or without type 2 diabetes who are candidates for duodeno-ileal anastomosis.
Features
- Magnetic compression technology for creating anastomoses without incisions, sutures, or staples
- MagDI™ System for side-to-side duodeno-ileal anastomosis
- Facilitates natural tissue healing at the anastomosis site
- Minimally invasive approach reduces patient trauma and recovery time
- Designed to promote durable weight loss and improve glycemic control
- First-generation Magnet received FDA De Novo marketing authorization (DEN240013) in July 2024
- Second-generation MagDI™ System with 40mm and 50mm DI Magnets received FDA 510(k) clearances in October 2024 and February 2025